Share Name Share Symbol Market Type Share ISIN Share Description
Creo Medical Group Plc LSE:CREO London Ordinary Share GB00BZ1BLL44 ORD GBP0.001
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 19.75 30,795 08:00:00
Bid Price Offer Price High Price Low Price Open Price
19.50 20.00 19.75 19.75 19.75
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 25.16 -30.34 -15.00 36
Last Trade Time Trade Type Trade Size Trade Price Currency
10:36:09 O 10 19.565 GBX

Creo Medical (CREO) Latest News

More Creo Medical News
Creo Medical Investors    Creo Medical Takeover Rumours

Creo Medical (CREO) Discussions and Chat

Creo Medical Forums and Chat

Date Time Title Posts
03/2/202309:42Creo Medical Group... 2017483
03/12/201812:41First use of Speedboat in mainland Europe-
09/12/201614:52China Real Estate Opportunities3
27/6/201211:52having a look......1,095

Add a New Thread

Creo Medical (CREO) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Creo Medical trades in real-time

Creo Medical (CREO) Top Chat Posts

Top Posts
Posted at 30/1/2023 08:51 by bodgeman
From what I have read people are suggesting creo require a fund raise of between 15 to 25million to carry on past june - when their money runs out at current burn rates. Let's say its 25m. If the share price were to drop to 15p then market cap of creo would be roughly the same as their upper fund raise requirement.

Options - raise new capital against value of company. Who is going to do that. It makes no sense at the level required.
Share issue with 90+% dilution. Makes no sense either.
Unlikely there are sufficient grants or fund options with the welsh assembly.
I'm sure there are lots of other improbable scenarios.

If you had 25m and were considering funding creo then you would wait till the share price drops to 15p where you could almost buy creo outright or gain a controlling share for half of that and use the rest to fund their continuation past june. This would inevitably go hand in hand with cost cutting - smaller premises, smaller staff numbers. Ugly.

The most sensible option (for me) would be for a competitor or current partner to buy them out OR for a fund to buy them up,fund them through to 2026 when they start to turn a profit and sell on.

Where does this leave shareholders? Something is going to give soon.....

Posted at 27/1/2023 17:12 by protrader3
33 consecutive red weekly candles. Another miserable week for CREO. 19p and another all time low.
Posted at 20/1/2023 12:14 by protrader3
No doubt this company has great potential. The bi question is how can they raise £25 million without a share dilution. Surely this would take the share price even lower.
Posted at 18/1/2023 20:37 by 74tom
Posted at 15/1/2023 22:18 by protrader3
After 12 months of constant selling, the question is how low can this share price go? It is highly likely that we could see a share dilution in the not too distant future. Looking at the cash burn CREO will run out of money by mid summer and will surely need to raise capital.
Posted at 11/1/2023 08:38 by 74tom
Yep, I've taken a starter position this morning - will add more if / when they sort out the cash runway. I certainly think an equity investment at a level well above the current share price is a possibility given where they previously raised capital.

This is particularly impressive;

"The Pioneer programme sits at the heart of the sales process tracking doctors engaged with the business to join the programme. The Company tracks all customers through this five-step process, from engagement, through to purchasing of equipment, training and mentoring, before becoming users. During FY 2022, the number of physicians in the process doubled to more than 450 by Dec 2022. With 60 doctors trained in H1 and 90 during H2, this resulted in 80 confirmed users at Dec 22, a fourfold increase from the start of the period and in-line with the Board's expectations, and leaving a wider cohort of engaged clinicians which the Group will work to convert to regular users in H1 2023."

Posted at 11/1/2023 08:14 by 74tom
That's been known for a long time now though (see posts above) and is certainly priced in given the enterprise value of ~£31m vs ~£250m 12 months ago. There is a decent note from Cenkos (I know) that splits revenue between Kampative, Creo Device & consumables. They appear to have received a £1m up front payment from Intuitive Surgical & are lined up for another £9m over the coming 3 years, plus royalties from device usage via ISRG systems.

Certainly high risk, but I think this looks very interesting as a recovery play or potentially even an acquisition target. I.e. if ISRG are happy to pay them £10m in milestones + ongoing royalties, why not just take the whole lot for £40m, given they have a market cap of $95b?

The product is clearly very good, the issue is they are undercapitalised & early in the game.

Posted at 09/12/2022 12:48 by 74tom
Really surprised that CREO haven't announced a financing in the 5 weeks since I posted, the share price continues to fall and it's been nearly 2 months since this closed higher than it opened... the longer it goes on the higher the chances of a destructive placing sub 30p get. I suspect they are in denial and refusing to accept that the valuation has fallen so far - or maybe they have a trick up their sleeve. All will be revealed at some point in the next few months...
Posted at 03/11/2022 10:41 by 74tom
I've been watching this with interest for some time but have held off even opening a starter position given the current environment. Looking at the fundamentals, you'd have to think we are in bargain territory now though with shares having declined some 57% from the day they announced the Intuitive Surgical deal...

CREO have raised capital 3 times since their IPO back in Dec 2016;

IPO : £20m @ 76p
July 2018 : £48.5m @ £1.25
December 2019 : £51.9m @ £1.80
August 2021 : £36.3m @ £1.825

That's a grand total of £156.7m at an average share price of £1.38

The problem right now is their cash balance is quite clearly running out;

31/12/2021 : Cash and cash equivalents £43.5m
30/06/2022 : Cash and cash equivalents £26.1m

Stripping out working capital movements gave cash used in operations of £15.7m in the first 6 months of the year, a burn rate of £2.6m a month...

So assuming that trend has more or less continued, they will now be down to around £16m, equivalent to just 6 months of runway.

I very much doubt they can afford to risk leaving a capital raise much longer or else run the risk of severely diluting prior investors (it's already bad enough, but £30m @ 40p would represent 40% dilution which isn't disastrous, whereas the same amount at 20p very much would be!) I doubt they would want to run the risk of any kind of debt financing at present given interest rates and appetite for risk.

Interesting to see what they can work out - you'd have to think longer term life science investors in the US would be sniffing around at current levels but there is zero sign of that at present!

Posted at 04/1/2017 09:56 by pecuniarum copia
NOTE: This really is a ridiculously long thread header - so you may want to press "Skip Header"

Creo Medical Group is focused on the development and commercialisation of minimally invasive surgical devices, initially in the area of gastrointestinal (GI) surgery and lung cancer.

Creo Medical Group has conditionally raised £20 million through a placing with institutional and other investors at a placing price of 76 pence per ordinary share. Market capitalisation approximately £61.3 million.


Creo Medical Group PLC (CREO), admission to the AIM Market, 9 December 2016.

80,711,745 Issued and fully paid Ordinary Shares of £0.001 each


x x x

AIM rule 26 httPs://

RNS: 11 November 2021
Appointment of Joint Broker

CREO… announces the appointment of Numis as the Company's Joint Broker with immediate effect.
Cenkos Securities plc remains Nominated Adviser and Joint Broker to the Company.

RNS: 4 August 2022
Exercise of Options

...Application has been made for the admission of 105,947 new Ordinary Shares to trading on AIM ("Admission"). It is expected that Admission will occur at 8:00 a.m. on 10 August 2022. Following the exercise of the Options, Mr Bradshaw will hold 105,947 Ordinary Shares in the Company representing approximately 0.06 percent. of the Company's issued share capital.

...Following Admission, the Company will have 181,527,885 Ordinary Shares in issue with voting rights attached. The Company has no shares in treasury; therefore upon, and subject to, registration, the total number of voting rights in Creo will be 181,527,885.

x x x [22 June 2020]
And we're live! We're so excited to share our new website! Join us on our journey to improve patient outcomes with #AdvancedEnergy. Explore: httP://

CREO Admission Document, Dec.2016, PDF

2019 AIM Awards ~ Best AIM companies > Technology = Creo Medical

2020 Video Abstracts ~ Use of Speedboat-RS2...

RNS: 11 February 2020 - Video abstracts featuring Speedboat procedures in India

and also

RNS: 3 August 2020 ~ Video abstract published endorsing Speedboat procedure

The video abstract, published via an open access content publisher, Thieme Group titled: 'Feasibility of Speedboat RS2 with bipolar radiofrequency energy for peroral endoscopic myotomy in patients with achalasia (with video)' can be viewed online here:

x x x


Documents are available on the Company's website:

Chepstow, Wales - 20 April 2018 - Creo Medical Group plc (AIM: CREO) ("Creo" or the "Company"), a medical device company focused on the emerging field of surgical endoscopy, announces that it has changed its accounting reference date from 30 June to 31 December with immediate effect.

Interim and annual reports will be published each year for the 6 months to 30 June and 12 months to 31 December respectively, in accordance with the AIM Rules for Companies.

Unaudited interims for the 6 month period ending 30 June 2018 to be published by 30 September 2018,
Audited results for the 18 month period to 31 December 2018 to be published by 30 April 2019.

Note: 5 April 2019, CREO published Full results for the 18 months ended 31 December 2018.

x x x

Follow Link for Latest Shareholding Info...

AIM rule 26 httPs://

Latest Shareholding RNS...

13 July 2018: Conditional Placing of new Ordinary Shares [@ 125.pence]
23 December 2019: Result of Open Offer [@ 180.pence]
24 December 2019: Director / PDMR Shareholding
27 December 2019: Legal & General Assurance Soc. (LGAS) Below 3% from 3.26%
30 December 2019: TR-1 M&G Plc 5.54% from n/a
07 February 2020: Exercise of Options
19 February 2020: Issue of Equity and Long Term Incentive Plan ("LTIP")
04 March 2020: Exercise of Options
24 July 2020: Director / PDMR Shareholding
11 August 2020: Exercise of Options
24 November 2020: Exercise of Options
19 April 2021: Exercise of Options
30 April 2021: Total Voting Rights (157,940,390)
01 July 2021: Issue of Equity
20 July 2021: Award of Shares - Share Incentive Plan, Dir. Dealings & Issue of Equity
30 July 2021: Total Voting Rights (161,002,002)
12 August 2021: Proposed Placing to raise a minimum of GBP30 million
12 August 2021: Proposed Open Offer to raise up to approx. GBP5 million [@ 182.5pence]
6 September 2021: TR-1 The Capital Group Companies 7.16% total
7 September 2021: Share Capital will consist of 180,901,186 Ordinary Shares
30 September 2021: Total Voting Rights (180,901,186)
24 November 2021: Exercise of Options
30 November 2021: Total Voting Rights (181,009,186)
23 December 2021: Exercise of Options
31 December 2021: Total Voting Rights (181,099,186)
28 February 2022: Total Voting Rights (181,204,996)
4 August 2022: Exercise of Options
31 August 2022: Total Voting Rights (181,527,885)

x x x


RNS: 13 September 2018
First placement and use of Speedboat in South Africa.
Seven upper GI tract patients successfully treated.

Creo… today announces the successful first use of its Speedboat endoscopic advanced energy device in the upper gastrointestinal tract (GI) in seven patients in South Africa. This follows the appointment of the Company's South African sales and distribution partner, First Medical Company, in July 2018...

RNS: 17 September 2018
Extension of Distribution Agreement with Hoya Pentax Medical for the Asia-Pacific (APAC) region.
Creo Medical Education Programme to be initiated in APAC alongside Market Seeding beginning in Australia.

...Australia will be the first Asia Pacific territory in which Pentax will establish Creo's Clinical Education Program and subsequently seed the market. Pentax will purchase a minimum quantity of CROMA advance energy platforms and Speedboat instruments with the first products expected to be shipped within 3 months. Furthermore, Creo has agreed to extend the term of Pentax's distribution rights in each territory in which Pentax establishes Creo's Clinical Education Programme for a period of 5 years from the date on which Creo's products are registered in such territory...

RNS: 17 October 2018
Spain & Benelux Framework Distribution Agreements
Agreements covering Spain, the Netherlands, Belgium and Luxembourg

First shipment of products to mainland Europe

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that it has entered into two further framework distribution agreements to provide clinical training and market seeding across the Spanish, Belgian, Dutch and Luxembourg markets for Creo's CROMA advance energy platform and Speedboat products, ahead of their full commercial launch in 2019.

RNS: 3 December 2018
First placement and use of Speedboat in Europe

Creo… announces the successful first treatment of a patient in mainland Europe using its Speedboat device powered by the Company's CROMA electrosurgery advanced energy platform, in Seville, Spain.

Craig Gulliford, Creo's Chief Executive Officer, commented:
"Mainland Europe and the US are key markets for the Company and the successful completion of the first procedure in Spain is an important milestone as we roll-out our Clinical Education Programme across Europe initially through our distribution partners covering Spain, the Netherlands, Belgium and Luxembourg. The additional funds raised over the summer have allowed us to expand our training programme to target a wider international group of clinicians and we remain on track with our US commercialisation programme and look forward to updating shareholders on positive progress."

RNS: 16 January 2019
First use of Speedboat in the US

Creo... announces the successful first treatment of patients in the US using its Speedboat device powered by the Company's CROMA electrosurgery advanced energy platform.

Craig Gulliford, Creo's Chief Executive Officer, commented:
"The US is clearly a key market for the Company and the successful completion of the first procedures in the United States is another important milestone for us. Over the next few weeks and months we expect to see our Clinical Education Programme expand in the US and we will continue to update shareholders as our training-led commercialisation strategy advances."

RNS: 11 February 2019
Additional European Framework Distribution Agreement with PENTAX Medical
Agreement covering France, Germany and Italy

...Continuing Creo's education led commercial strategy, Pentax Europe will collaborate with Creo over an 18-month period to advance the roll out of Creo's Clinical Education Programme across these key markets in Europe, educating leading clinicians in the use of Speedboat and the CROMA platform with the aim of ensuring quality control and best patient outcomes...

...PENTAX Europe will commence seeding these markets with Creo's products, with the ultimate objective of entering into a formal long-term distribution agreement once the seeding phase has completed.

This agreement follows on from the PENTAX Medical (a division of HOYA Group) distribution agreement covering Asia-Pacific (APAC) which was extended in September last year, as well as the recently announced agreements covering Spain, the Netherlands, Belgium and Luxembourg. In addition, distribution agreements have already been signed covering the UK and South Africa...

RNS: 28 March 2019
Update on US Clinical Education Programme

Following the first successful treatment of patients in the US with Speedboat, announced in January 2019, Speedboat has now been used successfully by a further four GI surgeons. Furthermore, at a recent scientific conference, Speedboat was demonstrated during a live case to an audience of leading therapeutic GI endoscopists. During the same conference, many of these leading therapeutic endoscopists were able to get a hands-on introductory experience with Speedboat in a training environment with excellent feedback, in particular with regards to the safety profile Speedboat provides the endoscopist.

This brings the total number of doctors now trained in the US to six at five hospitals across the East and West coasts. Creo will be working very closely with these centres as further cases are carried out, along with providing a continuing Clinical Education programme.

RNS: 25 June 2019
First commercial orders for Speedboat

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that it has received its first commercial orders for its Speedboat device, the first in a range of gastrointestinal ('GI') devices to be cleared for use with the CROMA Advanced Energy platform which uniquely combines bipolar radiofrequency energy for precise tissue dissection along with microwave energy for highly controlled coagulation and tissue ablation.

The first purchase orders come from two US hospitals and follow on from the successful roll out of the Company's Clinical Education Programme in the US which has now trained seven leading GI Endoscopists across six hospitals. The purchase orders are a follow-on order of the disposable Speedboat devices following the initial sales of products for training purposes...

RNS: 10 September 2019
US Clinical Education Programme enters Phase II
First training course delivered by key US adopter trained by Creo

...As part of this new phase, three additional US clinicians have been trained by a US GI Endoscopists who performed his first clinical case earlier this year (RNS 1927N, 16 January 2019) and practices at a major US hospital, which was one of the first to place commercial orders for the Company's Speedboat device.

RNS: 26 September 2019
Framework Distribution Agreement for India
Indian doctors and nurses trained on Speedboat following signing

CREO... has entered into a Distribution Partner Framework Agreement (the "Agreement") with MEDITEK SYSTEMS ("Meditek"), to provide clinical training and market seeding across the Indian market for Creo's CROMA Advance Energy platform and suite of products, including the Speedboat device, ahead of their official launch.

RNS: 22 October 2019
Commercial Launch of Speedboat at UEG Week in Barcelona [21/23 Oct.19]
Demonstration of wider suite of gastro-intestinal products awaiting regulatory clearance

...Creo will be exhibiting at the United European Gastroenterology ('UEG') Week Congress in Barcelona from 21-23, October 2019 show-casing the CROMA Platform...

Craig Gulliford, Chief Executive Officer, commented:

"The full commercial launch of the Speedboat device, coupled with the opportunity to show-case the wider suite of products at this key event, is another important step for the Company. In addition to the profiling of our technology in the exhibition area, we will also be using the time together with our distribution partners throughout Europe to outline the initial roll out plans for the wider portfolio and use this fantastic opportunity to build further excitement and momentum as we head into 2020."

RNS: 20 November 2019
First in-human cases in India
Asia's First POEM procedure undertaken using Speedboat

Creo… announces that the first mentored, in-human use of its Speedboat device has taken place in India. This announcement follows on from the framework distribution agreement the Company signed with Meditek Systems in September 2019 to provide clinical in-country training, mentoring and market seeding in India for Creo's CROMA Advanced Energy Platform and suite of products.

To date, Medical staff from six key healthcare institutions across India have completed training as part of Creo's Clinical Education Programme and the start of in-country mentoring was marked with the first 2 upper GI POEM (Peroral Endoscopic Myotomy) procedures being performed using Speedboat. These are the first POEM procedures in India carried out using the Speedboat device and show the significant advances made towards the future of endoscopic surgery.

The procedures were performed by Dr Amit Maydeo and Dr Gaurav Patil at the BIDS (Baldota Institute of Digestive Sciences) hospital in Mumbai... With further mentored clinical cases planned in the coming days in Delhi, Pune and Hyderabad, the expansion of Speedboat and the CROMA Advanced Energy Platform continues to gather pace.

As well as India and the US, patients have now been successfully treated using the Speedboat device powered by Creo's CROMA Advanced Energy platform in the UK, South Africa and Mainland Europe.

RNS: 2 December 2019
Fundraising, including Firm Placing, to raise a minimum of GBP43.0 million
Launch of Accelerated Book Build
Open Offer to raise up to GBP6.6 million [issue price 180 pence]

Craig Gulliford, Creo's Chief Executive Officer, commented: "The injection of additional funds ensures that we can fully capitalise on the growing opportunity that endoscopic surgery offers and will help to accelerate the commercial roll-out of our wider suite of patented electrosurgical devices powered by the CROMA Advanced Energy Platform. This also provides us with a platform to explore potential strategic acquisition opportunities in areas where we can identify adjacent technologies or infrastructure that will support our ambitious growth plans."

RNS: 23 December 2019
Result of Open Offer

CREO... raised total gross proceeds of GBP1.9 million via the Open Offer. Accordingly, the Company has conditionally raised total gross proceeds of GBP51.9 million via the Fundraising.

RNS: 30 January 2020
Trading Update for the year ended 31 December 2019 has been in-line with expectations and the Company continues to make progress in the commercialisation of the CROMA Advanced Energy Platform ("CROMA") and a suite of patented electrosurgical devices.

...The Company expects to see significant growth during 2020 in commercial orders for its Speedboat device. It is in the final stages of agreeing a third-party manufacturing contract to facilitate larger scale production. The Company has already validated the first batches of products from the third-party manufacturer and is confident of the high quality and consistency of production.

Craig Gulliford, Chief Executive Officer of Creo, commented:
"Following the completion of our suite of products and the development of our distribution network over the last 12 months, the whole team is gearing up for clinical activity with multiple devices. This is based around both existing and new customers and users. The new devices include, what we believe to be, the only triple mode bipolar surgical scissors, the smallest microwave ablation device, and the only non-stick haemostasis device.

"Having delivered initial revenues last year, the next few months mark a significant step up for the business. With much appreciated shareholder support, we now have a unique opportunity with game changing devices to develop the business. We are excited to be bringing these capabilities to both endoscopists and surgical users in many disciplines over the next few years. These achievements are testament to the hard work, passion and dedication of the extended Creo team."

RNS: 23 March 2020
US FDA Clearance for HS1 Haemostasis Device

CREO… the medical device company focused on the emerging field of surgical endoscopy, announces that it has received 510(k) clearance from the US Food & Drug Administration ('FDA') for its HS1 Haemostasis device ('HS1'). The HS1 will be used with Creo's CROMA Advanced Energy Platform ('CROMA') and alongside the already FDA-cleared Speedboat device.

This news represents a significant milestone for the Company, being the first of a number of expected regulatory clearances which will bring a suite of devices to the flexible endoscopy markets in the EU and USA...

RNS: 20 May 2020
Commercialisation Agreement

CREO… announces that it has signed a commercialisation agreement with the Department of Health and Social Care to provide NHS Hospitals with access to the Company's CROMA Advanced Energy Platform ("CROMA") and associated devices for use in Gastrointestinal ("GI") therapeutic endoscopy at preferential rates for a limited period.

The National Institute for Health Research ("NIHR") Invention for Innovation ("i4i") Programme supported certain development projects that Creo undertook via a series of funding awards between 2010 and 2015, totalling close to GBP2 million. In accordance with the terms of such funding, Creo has entered into this commercialisation agreement, which is designed to aid the roll-out of CROMA and accompanying consumable GI devices in the UK. The agreement also provides for training for clinicians and nurses on the use of Creo's suite of advanced energy surgery products...

RNS: 3 June 2020
Positive NHS health economics data
Savings of nearly GBP5,000 per procedure using Speedboat instead of traditional surgery

CREO... announces that initial data from the UK's leading user of the Company's Speedboat device demonstrates that the use of Speedboat can save NHS hospitals nearly GBP5,000 per procedure versus a traditional surgical outcome for patients. Health economic data analysed from a cohort of UK patient cases is estimated to have saved in excess of GBP400,000 of NHS funding in just one hospital...

...The full data is expected to be published in October 2020 and the overall costs savings could be higher when the additional follow up costs associated with surgery is factored in. A further announcement will be made once the data is published in full.

RNS: 15 June 2020
CE mark for five new devices
Key commercial milestone with launch of full suite of GI products

CREO… announces a key commercial milestone, with the simultaneous CE marking of five new devices which form the Creo GI (gastro-intestinal) suite of advanced energy devices across four technology platforms. The CE marking of the full range of products provides EU and UK clearance ahead of their commercial launch. Creo expects to introduce the devices into clinical practice and prepare for commercialisation in the second half of the year.

The range is designed to be used with the CROMA(TM) Advanced Energy Platform (CROMA), powered by Kamaptive(TM) full-spectrum adaptive technology, a seamless, intuitive integration of multi-modal energy sources, optimised to adapt to the tissue effect required for different procedures.

The heavily patented devices are individually optimised to utilise Bipolar radiofrequency (RF) and High frequency microwave (MW) energy for the core tissue effects of dissection, resection, haemostasis and ablation, and form the basis of four individual device platforms...

...The newly CE marked products are:
Speedboat(TM) Slim
SpydrBlade(TM) Flex
MicroBlate(TM) Fine
MicroBlate(TM) Flex
SlypSeal(TM) Flex

RNS: 2 July 2020
Development loan for plasma sterilising product
CREO advanced energy platform to combat COVID-19
Cardiff Capital Region City Deal funding to supports CREO Plasma Division

CREO... announces that the Group has secured a GBP2m loan from the Cardiff Capital Region ("CCR") to develop Creo's Cool Plasma technology as a method to kill bacteria and viruses and for sterilisation purposes. Creo's technology has both medical and non-medical applications and initial testing has demonstrated that it can be effective for COVID-19 inactivation and decontamination. The Company believes that the technology has the potential for use in wound care, medical device sterilisation, PPE sterilisation, endoscope sterilisation to kill the bacteria associated with urinary tract infections, as well as general sterilisation and cleaning of enclosed environments within the service and transport sectors...

RNS: 6 July 2020
Directorate Change, Appointment of Chief Commercial Officer to the Board
Further strengthening of Senior Management team

CREO... announces the following change to the Board and strengthening of the Senior Management team.

Appointment of David Woods as Executive Director (previously Non-Exec)

David Woods, Non-Executive Director, has been appointed as Chief Commercial Officer ('CCO'), with effect from 1 August 2020. David has extensive experience in the med-tech sector and joins the Company in his new full-time executive role based in the USA, having previously been the President and CEO of PENTAX Americas and M&A Director of HOYA Group PENTAX Medical...

RNS: 24 July 2020
Acquisition of Albyn Medical S.L.

Supplier of specialist healthcare products adds European commercial platform to Creo

CREO... announces the acquisition of Albyn Medical S.L. ("Albyn Medical"), a European specialist in the supply and manufacture of Gastroenterology, Urology and Endoscopy products to healthcare providers, for an equity value of EUR24.8m plus up to EUR2.7m of performance related consideration payable over the next two years.

Synergistic acquisition that provides immediate market access

With a sales and marketing team of nearly 40 people and a direct presence in Spain, France, Germany and the UK, the acquisition of Albyn Medical fits with the strategy set out by Creo at the time of its fundraising last year and provides it with a commercial and distribution platform to accelerate the development of its business in Europe. Albyn Medical focuses on gastrointestinal ( " GI") products and the acquisition provides a direct route-to-market for Creo's full suite of CE marked GI advanced energy devices...

RNS: 23 September 2020
Half-year Report

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces its unaudited results for the six-month period ended 30 June 2020, in line with management expectations...

RNS: 2 November 2020
US FDA clearance for MicroBlate (TM) Fine device

CREO... announces that it has received 510(k) clearance from the US Food & Drug Administration ('FDA') for its tissue ablation device MicroBlate (TM) Fine.

This is the third device to gain FDA regulatory clearance within Creo's portfolio of flexible endoscopy devices for the gastrointestinal ('GI') market alongside SlypSeal(TM) Flex and Speedboat(TM) Inject. The range is designed to be used with the CROMA Advanced Energy Platform, powered by Kamaptive(TM) full-spectrum adaptive technology, a seamless, intuitive integration of multi-modal energy sources, optimised to adapt to the tissue effect required for different procedures such as resection, dissection, coagulation and ablation of tissue...

RNS: 3 November 2020
Acquisition of Boucart Medical SRL

Belgium based supplier of GI Endoscopy products, complementing Albyn Medical's product range

CREO... is pleased to announce the acquisition of Boucart Medical SRL ("Boucart Medical"), the largest independent supplier of gastrointestinal ("GI") endoscopy consumables in Belgium and Luxembourg, for an initial consideration of EUR4.5 million in cash (subject to closing adjustments for cash, debt and working capital) plus up to EUR0.5 million of performance related consideration payable in cash over the next two years...

RNS: 9 December 2020
First clinical use of new Creo GI product

CREO... announces the first in-man clinical use of its MicroBlate(TM) Fine device, believed to be the world's smallest fine needle microwave ablation device available for clinical practice. The device was used to successfully ablate pancreatic tumour tissue under Endoscopic Ultrasound guidance, without any procedural complications...

RNS: 7 January 2021
US FDA clearance for MicroBlate (TM) Flex device

CREO... announces that it has received 510(k) clearance from the US Food & Drug Administration ('FDA') for its tissue ablation device MicroBlate(TM) Flex.

MicroBlate(TM) Flex is the fourth device within Creo's portfolio of flexible endoscopy devices for the gastrointestinal ('GI') market to receive FDA regulatory clearance, alongside CE marking already received across the range in 2020. The first Creo product to receive FDA clearance, Speedboat(TM) Inject, is being used by clinicians in the UK, EU, US, South Africa and APAC...

RNS: 17 February 2021
Trading update

Strong regulatory and commercial progress achieved despite worldwide COVID-19 restrictions

CREO… announces that trading for the year ended 31 December 2020 was marginally ahead of management expectations, with revenue for the year ended 31 December 2020 increasing to over GBP9m (2019: GBP0.01m). The Company had a net cash position at 31 December 2020 in excess of GBP45m...

Craig Gulliford, Chief Executive Officer of Creo, commented: "Despite COVID-19 having a short-term impact on the business, the last 12 months has been a period of transformational change for the Company. At the start of the pandemic, we asked the Creo team to focus on what they can achieve not what they can't achieve; I believe that they have done just that.

"In addition to stepping up to provide our own COVID response in local communities, we have gained further CE marks and FDA regulatory approvals for our devices, organically grown talent and completed the acquisitions of Albyn Medical S.L. and Boucart Medical SRL . The regionalised nature of the Group's business hedges against pandemic related travel restrictions. With the roll out of COVID-19 vaccines underway, we look forward to realising our goals this year and beyond."

RNS: 19 May 2021
Trading update
Q1 trading ahead of management's expectations
Increase in elective surgeries driven by need to reduce case backlogs

CREO… provides an update on progress and Q1 2021 trading, which is ahead of management's expectations. As a result, the directors have upgraded guidance for year-end revenue performance by at least 10%.

As previously stated, trading for the year ended 31 December 2020 was ahead of management's expectations, and the Company expects to report revenues of over GBP9m (2019: GBP0.01m) when it publishes its Audited Report and Accounts in early June...

Craig Gulliford, Chief Executive Officer of Creo, commented: " The worldwide uncertainty created by COVID-19 continues; however, the team at Creo has delivered exceptional results across many fronts including, making significant clinical and technical advances, building a global commercial team, finding innovative ways to train clinicians and continuing to deliver revenue ahead of management's expectation into the new financial year. We are delighted with the progress that has been made and believe our products will have a big part to play in reducing costs associated with traditional open surgery, reducing the huge backlogs for elective surgery that have built up during the pandemic, and most importantly providing better outcomes for patients globally."

RNS: 26 May 2021
Further health economics data validates technology

CREO… announces that data from the paper titled: 'Cost-effectiveness analysis of Speedboat submucosal dissection in the management of large non-pedunculated colorectal polyps' demonstrates that the use of Speedboat Inject is highly likely to be a cost-effective strategy for treating both benign and malignant large non-pedunculated colorectal polyps(1) ("LNPCP") and can lead to cost savings in NHS Hospitals of over GBP10,000 per procedure versus a traditional surgical outcome for patients, a saving of approximately 50 per cent. This is double the saving of that which was first suggested and announced by Creo in June 2020...

Craig Gulliford, Chief Executive Officer of Creo, commented: "We are extremely pleased to see this health economics data providing evidence that our Speedboat procedure could save the NHS over GBP10,000 per procedure. Our passion has always been to improve patient outcomes, not only through developing innovate medical devices to bring advanced energy to endoscopy, but to also offer economic benefits to healthcare providers, in turn allowing their limited resources to be applied elsewhere; this data demonstrates that. Following the commercial agreement we signed with the Department of Health and Social Care in 2020, offering health service bodies access to our devices at preferential rates, we continue our efforts to train more surgeons to use our technology, allowing the patients and NHS to benefit."

RNS: 4 June 2021
Final results for the 12 months ended 31 December 2020
A Transformational Year: Significant growth and continued regulatory progress

CREO… announces its audited final results for the 12 months ended 31 December 2020.

The Board is pleased to be able to report that, despite the COVID-19 pandemic, the year ended 31 December 2020 was a strong period for Creo marked by significant internal development and expansion, along with the continued development of the Company's suite of devices to complement the Company's CROMA Advanced Energy Platform ("CROMA") and Speedboat device for use in Gastrointestinal ("GI") therapeutic endoscopy...

Financial Highlights :
Total sales in the period were GBP9.4m (2019: GBP0.01m)
Cash and cash equivalents of GBP45.1m at 31 December 2020 (31 December 2019: GBP81.0m)

Operating loss of GBP23.5m (2019: GBP18.9m) including GBP0.7m share based payments, in line with management expectations and reflects increased R&D and commercial activities.
Net cash outflow from operating activities of GBP16.3m (2019: GBP11.9m)

RNS: 14 June 2021
Acquisition of freehold site for GBP4.25m
Expansion of Chepstow footprint to support commercial roll-out

CREO… announces that it has exchanged contracts to acquire the freehold interest in the current site of Creo House, the Company's main headquarters in Chepstow ('Unit 2'), as well as the adjacent site ('Units 6-9') for a total consideration of GBP4.25 million in cash. Creo expects to complete the acquisition in early July...

Craig Gulliford, Chief Executive Officer of Creo, commented: " We are delighted to have secured the freehold of Creo House as well as the adjacent site which, subject to planning permission, will provide increased capacity to support our commercial, operational and logistic footprint across Europe; as well as providing additional manufacturing capacity for the commercial roll-out of the full suite of advanced energy devices. By acquiring these sites, we are not only showing a firm commitment to Wales, but we are also giving our workforce even greater stability. The expansion is reflective of the rapid growth within Creo."

RNS: 16 June 2021
MicroBlate Fine's first in-human use update
Life-changing FDA cleared Creo device successful in adding months to patient's life expectancy and well-being

CREO… provides an update on its 510(k) US Food & Drug Administration ('FDA') cleared tissue ablation device MicroBlate(TM) Fine...

Craig Gulliford, Chief Executive Officer of Creo, commented:
"We are delighted to report such a positive update on our 510(k) US Food & Drug Administration cleared tissue ablation device MicroBlate(TM) Fine. The device was successfully used for the first in-human minimally invasive EUS guided treatment in a patient with an unresectable pancreatic neuroendocrine tumour in December 2020. The outcome of the procedure was a success, with subsequent follow up scans not only showing no return of the tumour, but also an absence of any obvious scar tissue."

RNS: 6 July 2021
Completion of freehold site for GBP4.25m

CREO… confirms that further to the announcement of 14 June 2021, that it has completed the freehold purchase of Creo House, the Company's main headquarters in Chepstow, as well as the adjacent site, from Fastnet Property Investments Limited, the original developer of the site.

RNS: 16 July 2021
Opening of United States, East Coast Headquarters

CREO… announces that it has opened its United States headquarters at the Summit, Danbury, Connecticut, USA...

Craig Gulliford, Chief Executive Officer of Creo, said: "We are delighted and proud to have opened our first United States facility, illustrating our commitment to growth and our focus on the key United States Market. These new premises will provide an excellent working environment for our United States team and a platform to attract further talent in this key region of the United States market."

David Woods, Chief Commercial Officer of Creo, commented: "Since my appointment in August last year, I have been busy assembling an experienced team to help capitalise on our continued evolution and expansion as a leading medical device Company. The opening of this clinical training and commercial support facility in the United States represents the next phase in our planned and sustained development and further illustrates our growth and focus in the United States region, which gives even greater access to another important market."

RNS: 12 August 2021
Proposed Placing to raise a minimum of GBP30 million
Launch of Accelerated Book Build
Proposed Open Offer to raise up to approximately GBP5 million

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy is pleased to announce a proposed Placing by way of an accelerated bookbuild to raise a minimum of GBP30 million (before expenses) via a conditional placing of new Ordinary Shares at the issue price of 182.5p per share to new and existing institutional investors, to support further growth of the Group and development of its business. The accelerated book build process is expected to close on 13 August 2021, following which the final quantum of the Placing proceeds will be announced.

Furthermore, the Company is proposing to raise up to approximately GBP5 million by way of an Open Offer which will be available to all Qualifying Shareholders on the Record Date…

...A circular, containing further details of the Fundraising and notice of the General Meeting to be held at 10.00 a.m. on 6 September 2021 to, inter alia, approve the Resolutions required to implement the Fundraising, is expected to be published and despatched to Shareholders on 16 August 2021 (the "Circular"). Following its publication, the Circular will be available on the Company's website at httPs://

RNS: 13 August 2021
Result of Placing

The Company is pleased to announce that, further to the announcement made on 12 August 2021 (RNS No:5145I) regarding the Fundraising (the "Launch Announcement"), an aggregate of 17,123,288 Placing Shares have been successfully placed by Cenkos Securities plc at an Issue Price of 182.5 pence per share to raise gross proceeds for the Company of approximately GBP31.25 million...

...This announcement should be read in conjunction with the full text of the Circular to be posted to Shareholders on 16 August 2021, copies of which shall be available on the Company's website at

RNS: 6 September 2021
Results of Placing and Open Offer and Result of General Meeting

On 16 August 2021, Creo announced it had raised GBP31.25 million by way of a conditional Placing and subsequently launched an Open Offer to raise up to an additional GBP5.07 million.

The Company is pleased to announce that at its General Meeting held today all of the resolutions, as set out in the Circular dated 16 August 2021, were duly passed.

The Company is also pleased to announce the results of the Open Offer, which closed for acceptances at 11:00 a.m. on 3 September 2021 and was significantly oversubscribed. Valid acceptances have been received in respect of 6,609,936 Open Offer Shares, representing 238.1 per cent. of the Open Offer Shares available under the Open Offer…

...The Company has therefore raised gross proceeds of approximately GBP5.07 million through the Open Offer.

Application has been made for a total of 19,899,184 new Ordinary Shares, to be issued pursuant to the Placing and Open Offer to be admitted to trading on AIM. It is expected that Admission and dealings in the 19,899,184 new Ordinary Shares will commence at 8.00 a.m. on 7 September 2021. Following Admission, the Enlarged Share Capital of the Company will consist of 180,901,186 Ordinary Shares.

RNS: 30 September 2021
Half-year Report

CREO… announces its unaudited results for the six-month period ended 30 June 2021.

Total sales in the period of GBP12.9m (H1 2020: GBP0.0m)

Cash and cash equivalents (before post-period equity raise) of GBP30.6m at 30 June 2021 (H1 2020: GBP70.6m)

Operating loss of GBP11.4m for H1 2021 (H1 2020: GBP10.6m) including GBP0.6m share based payments (H1 2020: GBP0.5m), in line with management expectations

Net assets of GBP52.2m at 30 June 2021 (H1 2020: GBP74.2m)

Strengthened IP portfolio, with 326 granted patents and 810 pending applications as at 31 August 2021

RNS: 11 November 2021
Appointment of Joint Broker

CREO… announces the appointment of Numis as the Company's Joint Broker with immediate effect.
Cenkos Securities plc remains Nominated Adviser and Joint Broker to the Company.

RNS: 12 November 2021
Acquisition of Aber Electronics Limited

CREO… announces the acquisition of Aber Electronics Limited ("Aber"), a UK based manufacturer and designer of power amplifiers and radio frequency products, for a fixed cash consideration, plus a contingent consideration over three years.

Creo is an existing customer of Aber, using its products within the CROMA Advanced Energy Platform. This acquisition will complement Creo's research, design and manufacturing processes, provide additional specialist microwave and radio frequency capability and expertise within the business and enhance a key element of the Group's supply chain. Creo anticipates leveraging the additional resource and expertise that it has acquired to further develop its Kamaptive Technology, the advanced energy which powers the CROMA Platform…

RNS: 24 January 2022
Licensing & Partnership update

CREO… provides an update on its Kamaptive Technology ("Kamaptive") licensing and partnership programme.

The Company has entered into non-binding heads of terms (the "HoTs") with a number of parties which relate to the Company's SpydrBlade, Cool Plasma and MicroBlate technologies. As outlined previously, Creo is developing its business through a three-tiered Build, Buy and Partner strategy. Having already demonstrated execution on the Build and Buy elements, the Partner strategy aims to create shareholder value through granting third-party access to Creo's advanced energy technology in markets adjacent to those where the Company is already operating. This includes fields such as laparoscopic surgery, robotically assisted surgery, and non-thermal plasma sterilisation.

The Company considers these HoTs, to be a key milestone in achieving its stated goal of licensing its technology to established, multi-national partners and is in line with the strategy set out at the time of its fundraising last year. Negotiations on final legally binding agreements are underway and Creo is mobilising resources to deliver against its obligations. The Company will update shareholders as appropriate in due course...

RNS: 3 February 2022
Trading update
Strong progress against 'Build, Buy and Partner' strategy
Revenues ahead of expectations

CREO… announces a trading update for the year ended 31 December 2021, as the Company continues to deliver on its three-tiered 'Build, Buy, and Partner' strategy...

...Creo trained a significant number of leading clinicians in 2021, who are now product users, and the Company expects this number to rise in 2022. In order to service this increased demand, Creo has increased its direct sales force by 25% since the beginning of 2021...

...As at 31 December 2021 the Company had a net cash position of approximately GBP44 million...

...Craig Gulliford, Chief Executive Officer of Creo, commented:
"I am pleased to report on what has been a successful year for Creo, with strong progress against our 'Build, Buy, and Partner' strategy. We have seen significant growth in commercial orders and adoption of Speedboat Inject in the US and Europe, the successful acquisition of Aber Electronics, as well as agreeing HoTs with a number of third parties to provide access to our advanced energy technology. Particularly encouraging has been completing the transition from a distribution model in core markets to an integrated direct sales team, built from the ground up in the US and through successful integration of Albyn Medical into our European business.

"We see the COVID-19 outlook improving, with an increased backlog of doctors gearing up to perform procedures as staffing challenges reduce, and restrictions ease across the globe.

"2022 has already started positively, with strong performances seen from our core product portfolio. Throughout the rest of the year, we look forward to continuing to execute and expand our three-tiered strategy through the education and training of clinicians, the roll-out of our product portfolio in APAC and further commercial orders and adoption of Speedboat Inject in the US and Europe. With our strong cash position and clear strategy, Creo is well positioned to deliver shareholder value in 2022. We look forward to updating shareholders in more detail in due course."

RNS: 4 February 2022
Award of Shares under Share Incentive Plan, Director Dealings, Issue of Equity and TVR

...The Company has been notified that Yorkshire Building Society, the independent trustee of the SIP, acquired, in accordance with the SIP's rules and on behalf of SIP participants, 54,404 ordinary shares in the Company ("Ordinary Shares"), at a price of GBP1.277 per Ordinary Share to meet its obligations under the SIP. Under the terms of the SIP, the Company is required to issue to the SIP, two Ordinary Shares in the Company for each Partnership Share purchased, being 105,810 new Ordinary Shares (having taken into account 2,998 ordinary shares held by the Trust which were previously allocated to employees who ceased employment before the shares had vested). These new Ordinary Shares will be held by Yorkshire Building Society as trustee of the SIP...

Total Voting Rights (TVR)
The above figure of 181,204,996 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

RNS: 16 March 2022
Albyn Medical earn out update

CREO… provides an update on the earn out agreement related to the acquisition of Albyn Medical S.L. ("Albyn"), as announced on 24 July 2020.

...The Company confirms that due to the successful performance of Albyn, the Company has acquired 50% of the remaining 10% of the issued share capital of Albyn for a consideration of EUR1.2m and the first tranche of the Earn Out payment, being EUR1.7m, has been satisfied in cash.

The successful acquisition has increased the Group's revenue year-on-year and the integration of Creo's European direct sales teams is now yielding new users of the Group's core technology. Albyn is now operating under the Creo Medical brand with its product range offering a mix of proprietary technology, own-brand labelled and third-party devices providing diagnostic, therapeutic and hygiene / cross-contamination control to a customer base of over 4,600, including hospitals, hospital groups and doctors' offices in both the state and private sectors.

...Craig Gulliford, Chief Executive Officer of Creo, commented: "That the Albyn team have successfully fulfilled the acquisition earn out criteria shows that they are performing well in what has been a challenging period given the pandemic, and they are now a fully integrated part of the Group. We're delighted to see that the 'Buy' element of our 'Build, Buy, Partner' strategy is yielding positive results."

RNS: 20 April 2022
Creo opens Singapore regional hub
Commercial hub further strengthens Creo's footprint across Asia-Pacific region

CREO… announces that it has officially opened its regional hub in Singapore, with the first-class facility providing a multi-functional centre for the commercial roll-out of Creo's products across the Asia-Pacific ("APAC") region.

The facility will provide a base for Creo's staff working across the region and includes a training centre, demonstration room, service centre and conference room...

Craig Gulliford, Chief Executive Officer of Creo, said: "It's fantastic to see this regional hub officially open - it's a first-rate facility which allows Creo to build on the important groundwork already done as we step up and roll out our products to new and exciting audiences and markets.

"The demand is clear from the engagement we've already had, and this commercial hub is a key cog in turning that demand into users and, ultimately, better outcomes for patients across APAC, whilst helping to deliver on our 'Build, Buy and Partner' strategy."

RNS: 28 April 2022
Trading update and notice of results
Solid start to 2022, with revenues in line with expectations

CREO… announces a trading update for the first quarter of 2022 and confirms that it expects to publish its final results for the year ended 31 December 2021 in early May 2022.

Creo continued to build momentum during 2021 and, as announced in the Company's 3 February 2022 trading update, overall revenue for the year ended 31 December 2021 is expected to be just over GBP25m - in line with the upgraded market expectations for FY2021. This momentum has continued in 2022 YTD with Creo seeing a solid start to the year. Revenues for Q1 2022 are strong, supported by the commercial groundwork put in place during the COVID-19 pandemic, the reopening of markets post COVID-19 and the resultant backlog of demand for elective procedures, increased training and adoption of Creo's Speedboat Inject device.

Commercial activity from Creo's core products continues to grow, with notable contributions from the US, EMEA and Asia-Pacific ("APAC") markets where case volumes have increased quarter-on-quarter...

Craig Gulliford, Chief Executive Officer of Creo, commented: "I have been delighted with the start to the year that the Creo team has made, as we build on the momentum that we established in 2021. We have seen increased training and adoption of clinicians using Speedboat Inject, with March 2022 being our record month for US cases performed using the device.

"The new 'pioneer' training programme demonstrates our commitment to continually improving our training standards to ensure that clinicians are properly educated on the safe use of our products, and become long-term users of our technology. Although our APAC regional hub has only just recently opened, the local Creo team has already made strong progress in building relationships with distribution partners, and we expect the hub to be a strong driver for our international expansion going forward as restrictions are lifted around the region."

RNS: 23 May 2022
Final Results

Total sales in the period of GBP25.2m (FY 2020: GBP9.4m)
Cash and cash equivalents of GBP43.5m at 31 December 2021 (FY 2020: GBP45.1m), including GBP34.3m net raised through Placing and Open Offer in September 2021
R&D expenditure in the year was GBP12.9m (FY 2020: GBP10.2m)
Operating loss of GBP29.9m for FY 2021 (FY 2020: GBP23.5m) including GBP2.6m share based payments (FY 2020: GBP0.7m), in-line with management expectations
Net assets of GBP73.3m at 31 December 2021 (FY 2020: GBP62.8m)


Collaboration agreement with Intuitive
Creo technology to be adapted for use with robotic-assisted surgical platform

CREO… announces that it has signed a long-term, multi-year collaboration agreement (the "Agreement") with Intuitive to optimise certain Creo products to be compatible with Intuitive's robotic technology . Intuitive (Nasdaq: ISRG) is a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery.

Along with the optimisation of Creo's products, the Agreement provides a framework to allow joint clinical studies to be undertaken and includes a number of milestone payments to be made to Creo. Future royalty structures have also been agreed for any products which may be sold in the future…

RNS: 27 May 2022
Chief Financial Officer purchases 70,000 shares [@ 96.75pence]
Non-Executive Chairman purchases 15,435 shares [@ 97.18pence]

RNS: 3 August 2022
H1 2022 Trading Update

Increased revenues
Over 20% reduction in underlying EBITDA loss vs H2 2021
New revenue streams added
Commercialisation of core technology enabling Creo to take significant steps forward to profitability

CREO… announces a trading update for H1 2022 and confirms that it expects to publish its unaudited interim results for the six months ended 30 June 2022 in September 2022.

Building on the momentum seen in the final quarter of 2021, Creo had a strong first half of 2022 and is expecting to report an increase in revenue of over 10% against H2 2021 revenues; with the growth driven by Creo's core technology, including first revenues from the Company's Kamaptive licensing programme. Increases in revenue and gross margins, coupled with a reduction in underlying operating costs, means that Creo expects to report a reduction of over 20% in underlying EBITDA loss for H1 2022 compared to H2 2021. The commercialisation of the Company's products has also led to a reduction in the Group's cash burn, with the Company having taken positive steps towards being cashflow positive. Creo continues to be engaged with other licensing partners as well as potential strategic investors.

During H1 2022 the number of clinicians able to provide training on Creo's technology has doubled compared to the previous 6 months, contributing to a 100% increase in both the volume of procedures and regular users of Speedboat Inject internationally over the same period...

Creo Medical share price data is direct from the London Stock Exchange
Your Recent History
Creo Medic..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230203 10:57:00